Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 173.00 GBp
Change Today +0.30 / 0.17%
Volume 535.9K
VEC On Other Exchanges
As of 11:35 AM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

vectura group plc (VEC) Snapshot

169.30 GBp
Previous Close
172.70 GBp
Day High
173.90 GBp
Day Low
169.10 GBp
52 Week High
06/12/15 - 183.75 GBp
52 Week Low
10/16/14 - 113.75 GBp
Market Cap
Average Volume 10 Days
0.0090 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for VECTURA GROUP PLC (VEC)

Related News

No related news articles were found.

vectura group plc (VEC) Related Businessweek News

No Related Businessweek News Found

vectura group plc (VEC) Details

Vectura Group plc researches, develops, and commercializes novel therapeutic products and drug delivery systems for the treatment of airways-related diseases. The company’s marketed products include Seebri Breezhaler and Ultibro Breezhaler for the treatment of chronic obstructive pulmonary disease (COPD); AirFlusal Forspiro for the treatment of asthma and COPD; ADVATE for the treatment of haemophilia A; Adept for the treatment of surgical adhesions; and Extraneal for the treatment of peritoneal dialysis, as well as Asmasal and Asmabec for the treatment of asthma. Its generic products include VR315, VR506, and VR632 for the treatment of asthma; and Phase III clinical stage products include VR475 for the treatment of severe adult asthma, and VR876 for the treatment of pulmonary hypertension, as well as NVA237 and QVA149 for the treatment of COPD for which filed NDA to the Food and Drug Administration. Its Phase II clinical stage products comprise VR096 for anti-inflammatory asthma and COPD; VR647 for the treatment of paediatric asthma; VR179 for the treatment of cystic fibrosis; and VR736 for the treatment severe influenza. The company’s Phase I clinical stage products include VR475 for the treatment of severe adult asthma; and VR465 for the treatment for respiratory syncytial virus infection. Its pre-clinical stage products include VR588 and VR942 for the treatment of inflammatory airway diseases. The company also provides drug delivery technology platforms, such as PowderHale, a formulation technology that is designed to enhance the performance of dry powder inhaler products; PowderMax technology that applies PowderHale approach to spectrum of drug substances; and ParticleMax technology to create a new generation of formulations. In addition, it provides dry powder inhalers; nebulizer delivery systems; and AKITA Jet, APIXNEB, and FOX devices. Vectura Group plc was founded in 1997 and is headquartered in Chippenham, the United Kingdom.

297 Employees
Last Reported Date: 05/19/15
Founded in 1997

vectura group plc (VEC) Top Compensated Officers

Interim Chief Executive Officer, Chief Operat...
Total Annual Compensation: 506.0K GBP
Chief Financial Officer, Company Secretary an...
Total Annual Compensation: 127.0K GBP
Compensation as of Fiscal Year 2015.

vectura group plc (VEC) Key Developments

Vectura Announces Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Vectura announced earnings results for the second quarter and six months ended June 30, 2015. For the quarter, sales were SEK 42 million, EBITDA was SEK 27 million against sales of SEK 35 million, EBITDA of SEK 22 million and EBITA of SEK 4 million for the same period a year ago. Operating cash outflow was SEK 3 million against SEK 96 million a year ago. Capital expenditures were SEK 36 million against SEK 94 million a year ago. Sales growth was 20%, driven by continued positive development of rental income from Grand Hôtel and new Aleris facilities. For the six months, sales were SEK 70 million, EBITDA was SEK 42 million and LBITA was SEK 8 million against sales of SEK 61 million, EBITDA of SEK 35 million and LBITA of SEK 2 million for the same period a year ago. Operating cash outflow was SEK 40 million against SEK 103 million a year ago. Net debt was SEK 1,389 million against SEK 1,363 million as at December 31, 2014. Capital expenditures were SEK 61 million against SEK 163 million a year ago.

Vectura Group plc Announces Executive Changes

Vectura Group plc announced the appointment of James Ward-Lilley as CEO and Executive Director. James will succeed Dr. Chris Blackwell leaves Vectura at the end of June 2015. James joins the Group on October 1, 2015 from AstraZeneca, where he is currently Vice President Respiratory, Inflammation & Autoimmunity, GPPS (Global Product and Portfolio Strategy). In his current role James has responsibility for the development of AstraZeneca's RIA (Respiratory, Inflammation and Autoimmunity) strategy which has included the recent acquisitions of Almirall's respiratory business and Pearl Therapeutics. The Board confirms that Dr. Trevor Phillips will act as Interim CEO from the end of June 2015 until James Ward-Lilley joins the company as CEO.

Vectura Group plc(LSE:VEC) added to FTSE 250 (Ex Investment Companies) Index (GBP)

Vectura Group plc(LSE:VEC) added to FTSE 250 (Ex Investment Companies) Index (GBP)


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VEC:LN 173.00 GBp +0.30

VEC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VEC.
View Industry Companies

Industry Analysis


Industry Average

Valuation VEC Industry Range
Price/Earnings 100.0x
Price/Sales 12.4x
Price/Book 3.2x
Price/Cash Flow 29.5x
TEV/Sales 12.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VECTURA GROUP PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at